Funding Clinical Trials

Funding Clinical Trials

Our Agency funds clinical trials testing promising stem cell or gene therapies for currently incurable diseases or disorders to help patients with unmet medical needs. For basic information about stem cell trials, visit our Clinical Trials 101 page. For a list of clinical trials that are a result of early-stage CIRM grants click here.

CIRM Clinical Dashboard

Disease Areas Investigator Organization Phase Trial Statussort descending Targeted Enrollment Detail
Krystof Bankiewicz Brain Neurotherapy Bio Phase 1 Active, not recruiting 11
  • COVID-19
 Michael Matthay University of California, San Francisco Phase 2 Active, not recruiting 120
  • Pulmonary Hypertension
  • Vascular Disease
 Michael Lewis Cedars-Sinai Medical Center Phase 1/2 Active, not recruiting 26
William van der Touw Celularity Inc Phase 1/2 Active, not recruiting 86
Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 355
Robert Lowsky Stanford University Phase 1 Active, not recruiting 15
David Williams Boston Children's Hospital Phase 2 Active, not recruiting 10
Christine Brown City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 82
Manasi Jaiman ViaCyte, Inc. Phase 1/2 Active, not recruiting 75
  • Leukemia, Acute Myeloid (AML)
 Mark Chao Forty Seven Inc. Phase 1 Active, not recruiting 258
Michael Pulsipher Children's Hospital of Los Angeles Phase 1/2 Active, not recruiting 60
Daniel Brennan Medeor Therapeutics, Inc. Phase 3 Active, not recruiting 30
Mark Humayun University of Southern California Phase 1 Active, not recruiting 16
De-Fu Zeng City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 3
  • Immune Disease
  • Pediatrics
  • X-linked Chronic Granulomatous Disease
 Donald Kohn University of California, Los Angeles Phase 1/2 Active, not recruiting 16
  • Immune Disease
  • Leukocyte Adhesion Deficiency
 Kinnari Patel Rocket Pharmaceuticals, Inc. Phase 1/2 Active, not recruiting 9
John Zaia City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 12
Rachel Smith Capricor, Inc Phase 2 Closed 156
Gayatri Rao Rocket Pharmaceuticals, Inc. Phase 1 Closed 1
Robert Dillman Caladrius Biosciences Phase 3 Closed 4
Howard Foyt ViaCyte, Inc. Phase 1/2 Closed 19
  • Leukemia, Acute Myeloid (AML)
 Colleen Delaney Nohla Therapeutics Inc Phase 2 Closed 146
  • Multiple Myeloma
 Rajesh Belani Poseida Therapeutics, Inc. Phase 1 Closed 105
Thomas Kipps University of California, San Diego Phase 1 Completed 26
Irving Weissman Stanford University Phase 1 Completed 88
Dennis Slamon University of California, Los Angeles Phase 1 Completed 48
Mark Chao Forty Seven Inc. Phase 1/2 Completed 78
Henry Klassen jCyte, Inc Phase 2 Completed 84
Nancy Lane University of California, Davis Phase 1/2 Completed 58
William Sietsema Caladrius Biosciences Phase 2 Completed 113
Linda Marban Capricor, Inc Phase 2 Completed 25
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 10
Ralph Kern BrainStorm Cell Therapeutics Phase 3 Completed 263
Jane Lebkowski Geron Corporation Phase 1 Completed 5
Vicki Wheelock University of California, Davis Phase 1/2 Completed 29
Kristen Johnson Calibr Phase 1 Completed 60
Francois Binette Lineage Cell Therapeutics Inc. Phase 1/2 Completed 25
Bijan Nejadnik SanBio, Inc. Phase 2 Completed 163
Clive Svendsen Cedars-Sinai Medical Center Phase 1/2 Completed 18
Henry Klassen University of California, Irvine Phase 1/2 Completed 28
Henry Klassen jCyte, Inc Phase 2 Completed 84
  • Beta Thalassemia
 Bettina Cockroft Sangamo BioSciences, Inc. Phase 1/2 Completed 5
Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 42
Donald Kohn University of California, Los Angeles Phase 2 Completed 10
Geoff Symonds Calimmune, Inc. Phase 1/2 Completed 13
  • Alpha Thalassemia Major
 Tippi MacKenzie University of California, San Francisco Phase 1 Enrolling by invitation 10
John Zaia City of Hope, Beckman Research Institute Phase 1 Launching N/A
Steven Deeks University of California, San Francisco Phase 1/2 Launching N/A
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Launching N/A
Mark Walters University of California, San Francisco Phase 1 Launching N/A
  • Anemia
  • Bone Marrow Transplant and Viral Infection
 Alice Bertaina Stanford University Phase 1/2 Launching N/A
Ivan King Tachyon Therapeutics, Inc Phase 1 Launching N/A
Robert Hayes Immusoft Corporation Phase 1 Launching N/A
Thomas Chalberg Genascence Corporation Phase 1 Launching N/A
Jana Portnow City of Hope, Beckman Research Institute Phase 1 Launching N/A
  • Bladder or Urinary Tract Disorder
 James Yoo Wake Forest University Health Sciences Phase 1 Not yet recruiting 10
Saul Priceman City of Hope, Beckman Research Institute Phase 1 Recruiting 39
  • Corneal Damage
 Sophie Deng University of California, Los Angeles Phase 1 Recruiting 20
Clive Svendsen Cedars-Sinai Medical Center Phase 1 Recruiting 16
  • Spina Bifida
 Diana Farmer University of California, Davis Phase 1 Recruiting 55
Thomas Kipps University of California, San Diego Phase 1/2 Recruiting 138
Leo Wang City of Hope, Beckman Research Institute Phase 1 Recruiting 18
Jeffrey Lawson Humacyte, Inc. Phase 3 Recruiting 240
  • Leukemia, Acute Myeloid (AML)
 Joseph Woodard Immune-Onc Therapeutics Phase 1 Recruiting 122
Antoni Ribas University of California, Los Angeles Phase 1 Recruiting 12
Gary Steinberg Stanford University Phase 1 Recruiting 30
Crystal Mackall Stanford University Phase 1 Recruiting 54
  • B cell cancers
  • Leukemia
  • Leukemia, Acute Myeloid (AML)
 Matthew Porteus Stanford University Phase 1 Recruiting 22
  • B cell cancers
 Paul Finnegan Angiocrine Bioscience, Inc. Phase 3 Recruiting 148
Joseph Wu Stanford University Phase 1 Recruiting 18
  • IPEX Syndrome
 Rosa Bacchetta Stanford University Phase 1 Recruiting 36
Pamela Contag BioEclipse Therapeutics INC. Phase 1 Recruiting 24
  • Severe Combined Immunodeficiency, Artemis deficient (ART-SCID)
 Morton Cowan University of California, San Francisco Phase 1 Recruiting 25
  • Epilepsy
 Cory Nicholas Neurona Therapeutics Phase 1 Recruiting 40
David Miklos Stanford University Phase 1 Recruiting 60
  • Muscle Injury
 Peter Belafsky University of California, Davis Phase 1/2 Recruiting 62
Steven Dubinett University of California, Los Angeles Phase 1 Recruiting 24
Donald Kohn University of California, Los Angeles Phase 1 Recruiting 6
William Kennedy Excision BioTherapeutics Phase 1 Recruiting 9
Stephen Gottschalk St. Jude Children's Research Hospital Phase 1/2 Recruiting 28
Everett Meyer Stanford University Phase 1 Recruiting 22
Judith Shizuru Stanford University Phase 1/2 Recruiting 40
  • Sarcoma
 Theodore Nowicki University of California, Los Angeles Phase 1 Recruiting 12
Mehrdad Abedi University of California, Davis Phase 1/2 Recruiting 18
Peter Stock University of California, San Francisco Phase 1/2 Recruiting 8
Stephanie Cherqui University of California, San Diego Phase 1/2 Recruiting 6
Anthony Gringeri ImmunoCellular Therapeutics Phase 3 Suspended 414
Pierre Caudrelier ExCellThera Inc. Phase 1 Withdrawn N/A
Icon for XLSX export